多发性骨髓瘤患者的COVID-19疫苗接种:欧洲骨髓瘤网络的共识
欧洲骨髓瘤网络成员及外部专家通过虚拟会议和广泛文献检索,针对多发性骨髓瘤患者的COVID-19疫苗接种形成共识推荐。患者免疫受损且感染风险高,现有数据显示抗SARS-CoV-2免疫应答欠佳,部分患者未受保护;与应答不佳相关的因素包括疾病未控制、免疫抑制、合并治疗、更多治疗线数以及靶向CD38和B细胞成熟抗原的治疗。
要点
- 多发性骨髓瘤患者感染SARS-CoV-2及感染相关死亡风险增高,接种疫苗至关重要。
- 现有数据显示患者抗SARS-CoV-2免疫应答欠佳,部分患者未受保护。
- 应答不佳相关因素包括疾病未控制、免疫抑制、合并治疗、更多治疗线数及靶向CD38和BCMA治疗。
核心结论
- 监测多发性骨髓瘤患者对疫苗接种的免疫应答或可为临床管理提供指导,如给予同种或另一种疫苗的额外剂量,或尽可能暂时中断治疗。
- 对未表现出良好应答者,可考虑使用中和性单克隆抗体鸡尾酒进行预防性治疗。
- 对缺乏SARS-CoV-2免疫应答的患者,尤其推荐坚持降低感染风险的措施。
研究设计与样本
- 欧洲骨髓瘤网络成员及部分外部专家召开虚拟会议,进行广泛文献检索,评估近期发表数据、会议报告及自身研究结果,形成共识推荐。
主要发现
- 多发性骨髓瘤患者常存在显著免疫受损,感染和感染相关死亡风险增高,SARS-CoV-2感染风险及由此导致的死亡风险也增高。
- 现有数据提示患者抗SARS-CoV-2免疫应答欠佳,意味着部分患者未受保护。
- 与应答不佳相关的因素包括疾病未控制、免疫抑制、合并治疗、更多治疗线数以及靶向CD38抗体和靶向B细胞成熟抗原的治疗。
临床怎么用
- 监测患者对疫苗接种的免疫应答或可为临床管理提供指导,如给予同种或另一种疫苗的额外剂量,或尽可能暂时中断治疗。
- 对未表现出良好应答者,可考虑使用中和性单克隆抗体鸡尾酒进行预防性治疗。
- 对缺乏SARS-CoV-2免疫应答的患者,尤其推荐坚持降低感染风险的措施。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also increased, emphasising the importance of protecting patients by vaccination. Available data in patients with multiple myeloma suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected. Factors associated with poor response are uncontrolled disease, immunosuppression, concomitant therapy, more lines of therapy, and CD38 antibody-directed and B-cell maturation antigen-directed therapy. These facts suggest that monitoring the immune response to vaccination in patients with multiple myeloma might provide guidance for clinical management, such as administration of additional doses of the same or another vaccine, or even temporary treatment discontinuation, if possible. In those who do not exhibit a good response, prophylactic treatment with neutralising monoclonal antibody cocktails might be considered. In patients deficient of a SARS-CoV-2 immune response, adherence to measures for infection risk reduction is particularly recommended. This consensus was generated by members of the European Multiple Myeloma Network and some external experts. The panel members convened in virtual meetings and conducted an extensive literature research and evaluated recently published data and work presented at meetings, as well as findings from their own studies. The outcome of the discussions on establishing consensus recommendations for COVID-19 vaccination in patients with multiple myeloma was condensed into this Review.
引用
- Ludwig H, Sonneveld P, Facon T, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021. PMID: 34756169. doi:10.1016/S2352-3026(21)00278-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。